Report Highlights

Market Overview of Liver Biopsy in the U.S.

The U.S. liver biopsy market was valued at USD 412.6 million in 2024 and is forecast to reach USD 647.7 million by 2032. Procedure volume is concentrated in hospital outpatient departments and independent gastroenterology practices, while needles, core-tissue instruments and specimen-handling products are supplied by a small group of device manufacturers. Private companies have led product innovation, while the Centers for Medicare and Medicaid Services (CMS) has effectively set the commercial envelope through its fee schedules.

Government has been the dominant force on the demand side. Medicare payment rules, the Clinical Laboratory Improvement Amendments of 1988 (CLIA), administered by CMS, and FDA device classification under the Federal Food, Drug, and Cosmetic Act determine which sites perform biopsies and how pathology is billed. Shifts in clinical practice, particularly the move to noninvasive staging, have been driven by private clinicians and manufacturers such as Echosens, whose FibroScan platform sits outside the biopsy procedure base.

Policy-Driven Growth in U.S. Liver Biopsy

Medicare payment for percutaneous liver biopsy under CPT 47000 and pathology interpretation under CPT 88305 anchors procedure economics. Rates are updated each year through the CY2026 Medicare Physician Fee Schedule and the Hospital Outpatient Prospective Payment System, so each revision directly alters hospital willingness to perform biopsies in-house. The FDA's March 14, 2024 accelerated approval of resmetirom (Rezdiffra) for noncirrhotic MASH with moderate to advanced fibrosis keeps histologic staging central to treatment pathways, sustaining pathology demand.

The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), finalized in January 2024, requires impacted Medicare Advantage, Medicaid and CHIP payers to decide expedited prior authorization requests within 72 hours and standard requests within seven calendar days from January 1, 2026. Faster decisions remove scheduling delays for elective biopsies and convert deferred procedures into billable throughput. Pathology economics remain tied to the Clinical Laboratory Fee Schedule set under the Protecting Access to Medicare Act of 2014 (PAMA), which determines reimbursement per specimen.

Regulatory Barriers and Compliance Costs in U.S. Liver Biopsy

Biopsy needles, core-tissue instruments and specimen containers are regulated by the FDA's Center for Devices and Radiological Health (CDRH). Most new needle designs require 510(k) premarket notification under the Federal Food, Drug, and Cosmetic Act. The Medical Device User Fee Amendments set a 90-FDA-day review goal, but clearance commonly extends beyond that once additional information requests are issued, delaying launches and adding regulatory cost.

Laboratories processing biopsy specimens must hold a CLIA certificate issued by CMS, with inspection and proficiency testing requirements that add recurring compliance costs for smaller hospital labs. Sharps handling falls under the OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030), which mandates safety-engineered devices and pushes suppliers toward costlier redesigns. The FDA's laboratory-developed test rule was vacated by the U.S. District Court for the Eastern District of Texas in March 2025, leaving CLIA as the primary laboratory oversight.

Policy-Created Opportunities in the U.S. Liver Biopsy Segment

Veterans Health Administration hepatology programs procure supplies through Federal Supply Schedule contracts administered by the General Services Administration. This creates a procurement channel for FDA-cleared biopsy needles and specimen containers outside standard Medicare pricing. Suppliers holding these contracts gain access to a large, recurring institutional buyer with predictable order volumes.

The FDA Breakthrough Devices Program, established under Section 515B of the Federal Food, Drug, and Cosmetic Act by the FDA Safety and Innovation Act of 2012, offers priority interaction for sampling devices that address serious conditions. The CMS Transitional Coverage for Emerging Technologies (TCET) pathway, finalized in 2024, provides a coverage route for qualifying devices, rewarding developers of tissue-sparing or image-guided sampling systems with faster Medicare access.

Market at a Glance

Leading Market Participants

• Becton Dickinson
• Cook Medical
• Teleflex
• Merit Medical Systems
• Boston Scientific
• Olympus Corporation
• Echosens
• AngioDynamics
• Quest Diagnostics
• Labcorp

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, as amended by the Medical Device Amendments of 1976, administered by the FDA's CDRH. Compliance requires 510(k) clearance for new needle designs, device registration and listing, and quality system requirements under 21 CFR Part 820. The Quality Management System Regulation, which aligns those requirements with ISO 13485, takes effect February 2, 2026. The Medical Device User Fee Amendments (MDUFA V) fund review through September 30, 2027, so MDUFA VI reauthorization negotiations begin in 2026.

Compared with the EU Medical Device Regulation (EU) 2017/745, which requires notified-body certification for most invasive devices, the U.S. 510(k) route is generally faster for needle designs with established predicates. Health Canada's Medical Devices Regulations (SOR/98-282) apply a licensing model with similar device classification logic. The U.S. differs most in its laboratory layer, where PAMA-linked fee schedules and CLIA certification govern pathology economics in ways no EU or Canadian peer replicates.

Long-Term Policy Outlook for Liver Biopsy in the U.S.

The most consequential change before 2032 is CMS-0057-F's application programming interface requirement, which takes effect January 1, 2027. Combined with QMSR implementation in February 2026, these rules will raise documentation and compliance costs for smaller device suppliers. Established manufacturers able to absorb these costs will gain share as independent suppliers exit institutional contracts.

MASH therapy expansion will sustain histologic confirmation volumes through the forecast period. However, TCET-supported noninvasive tests and FibroScan-based staging will move a growing share of fibrosis assessment away from needles by 2032. The MDUFA VI cycle, beginning October 2027, will determine review timelines for next-generation sampling devices and shape which products reach market first.